Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1383-1390

  Finn, Andrew ^a   Collins, Jason ^b   Voyksner, Robert ^c   Lindley, Celeste ^b  

^a BDSI Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c LCMS Limited   (United States)

Author keywords

Antiemetic; Buccal; Metabolism; Prochlorperazine

Indexed keywords

NORPROCHLORPERAZINE; PROCHLORPERAZINE; PROCHLORPERAZINE 7 HYDROXIDE; PROCHLORPERAZINE SULFOXIDE; PROCHLORPERAZINE SULFOXIDE 4' N OXIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; SOMNOLENCE; VOMITING;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; ADULT; ANTIEMETICS; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; MALE; PROCHLORPERAZINE;

EID: 27844472832     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005281044     Document Type: Article

References (16)

1. Lipman AG. Drug therapy in terminally ill patients. Amer J Hosp Pharm. 1975;32:270-276.
2. Peroutka SJ, Snyder SH. Anti-emetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982;1:658-659.
3. Niemegeers CJ. Antiemetic specificity of dopamine antagonists. Psychopharmacology. 1982;78:210-213.
4. Fowler A, Taylor W, Bateman DN. Plasma prochlorperazine assay by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1986;380:202-205.
5. Taylor WB, Bateman DN. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987;23:137-142.
6. Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991; 32:677-684.
7. Isah AO, Rawlins MD, Bateman DN. The pharmacokinetics and effects of prochlorperazine in elderly female volunteers. Age Aging. 1992;21:27-31.
8. Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Contr Rel. 1999;62:149-159.
9. Khanvilkar K, Donovan M, Flanagan D. Drug transfer through the mucosa. Adv Drug Del Rev. 2001;48:173-193.
10. Hessell PG, Lloyd-Jones JG, Muir NC, Parr GD, Sugden K. A comparison of the availability of prochlorperazine following IM buccal and oral administration. Int J Pharmaceutics. 1989;52:159-164.
11. Collins JM, Lindley CM, Voyksner RD, Finn AL. In-vitro characterization of the metabolism of prochlorperazine. American Society for Clinical Pharmacology and Therapeutics. 2004;75(2):85.
12. Gralla R, Osoba D, Kris M, et al. Recommendations for the Use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
13. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729-764.
14. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol. 1998;9:811-819.
15. NCCN Antiemesis Practice Guidelines 2005. National Comprehensive Cancer Network Web site. Available at: http://www .NCCN.org.
16. Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy. Am J Clin Oncol. 2005;28:270-276.